BACKGROUND: Invasive candidiasis is a leading cause of morbidity and mortality in critically ill infants. Prompt administration of fluconazole and achievement of the therapeutic target (area under the curve 0 to 24 hours >400 mg*h/L) improve outcomes in candidemic patients. A loading dose of fluconazole is advised for older patients but has not been evaluated in infants. We sought to determine the pharmacokinetics and safety of a fluconazole loading dose in infants at risk for invasive fungal infection. METHODS: We enrolled 10 hospitalized infants <60 days old with suspected systemic fungal infection in this open-label study; 9 received a 25-mg/kg fluconazole loading dose followed by a maintenance dose of 12 mg/kg every 24 hours for 4 additional days. Plasma samples were obtained following the loading and steady-state doses (doses 3-5). We used a 1-compartment model to fit the data to estimate pharmacokinetic indices. RESULTS: Data from 57 drug concentrations obtained from 8 infants (median postnatal age, 16 days [interquartile range, 13-32] and median gestational age, 37 weeks [35-38]) showed that the median fluconazole area under the curve 0 to 24 hours (mg*h/L) in this population was 479 (347-496). Of the 8 infants who received the loading dose, 5 (63%) achieved the therapeutic target on the first day of dosing, and all infants achieved a fluconazole 24-hour trough concentration >8 μg/mL. No adverse events were thought to be related to fluconazole therapy. CONCLUSIONS: A loading dose of fluconazole (25 mg/kg) was safe in this small cohort of young infants and achieved the therapeutic target more rapidly than traditional dosing.
BACKGROUND:Invasive candidiasis is a leading cause of morbidity and mortality in critically ill infants. Prompt administration of fluconazole and achievement of the therapeutic target (area under the curve 0 to 24 hours >400 mg*h/L) improve outcomes in candidemic patients. A loading dose of fluconazole is advised for older patients but has not been evaluated in infants. We sought to determine the pharmacokinetics and safety of a fluconazole loading dose in infants at risk for invasive fungal infection. METHODS: We enrolled 10 hospitalized infants <60 days old with suspected systemic fungal infection in this open-label study; 9 received a 25-mg/kg fluconazole loading dose followed by a maintenance dose of 12 mg/kg every 24 hours for 4 additional days. Plasma samples were obtained following the loading and steady-state doses (doses 3-5). We used a 1-compartment model to fit the data to estimate pharmacokinetic indices. RESULTS: Data from 57 drug concentrations obtained from 8 infants (median postnatal age, 16 days [interquartile range, 13-32] and median gestational age, 37 weeks [35-38]) showed that the median fluconazole area under the curve 0 to 24 hours (mg*h/L) in this population was 479 (347-496). Of the 8 infants who received the loading dose, 5 (63%) achieved the therapeutic target on the first day of dosing, and all infants achieved a fluconazole 24-hour trough concentration >8 μg/mL. No adverse events were thought to be related to fluconazole therapy. CONCLUSIONS: A loading dose of fluconazole (25 mg/kg) was safe in this small cohort of young infants and achieved the therapeutic target more rapidly than traditional dosing.
Authors: Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards Journal: Clin Infect Dis Date: 2003-12-19 Impact factor: 9.079
Authors: J Nolla-Salas; A Sitges-Serra; C León-Gil; J Martínez-González; M A León-Regidor; P Ibáñez-Lucía; J M Torres-Rodríguez Journal: Intensive Care Med Date: 1997-01 Impact factor: 17.440
Authors: Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole Journal: Pediatrics Date: 2002-08 Impact factor: 7.124
Authors: J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine Journal: N Engl J Med Date: 1994-11-17 Impact factor: 91.245
Authors: P M Olaechea; M Palomar; C León-Gil; F Alvarez-Lerma; R Jordá; J Nolla-Salas; M A León-Regidor Journal: Eur J Clin Microbiol Infect Dis Date: 2004-03-13 Impact factor: 3.267
Authors: Kevin M Watt; Daniel K Benjamin; Ira M Cheifetz; Ganesh Moorthy; Kelly C Wade; P Brian Smith; Kim L R Brouwer; Edmund V Capparelli; Michael Cohen-Wolkowiez Journal: Pediatr Infect Dis J Date: 2012-10 Impact factor: 2.129
Authors: Simon B Ascher; P Brian Smith; Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez; Reese H Clark; Daniel K Benjamin; Cassandra Moran Journal: Pediatr Infect Dis J Date: 2012-05 Impact factor: 2.129
Authors: Kim C M van der Elst; Manouche van Alst; Marjolijn N Lub-de Hooge; Kai van Hateren; Jos G W Kosterink; Jan-Willem C Alffenaar; Elisabeth H Schölvinck Journal: Antimicrob Agents Chemother Date: 2014-09-02 Impact factor: 5.191
Authors: Laura E Miller; Chris DeRienzo; P Brian Smith; Carl Bose; Reese H Clark; C Michael Cotten; Daniel K Benjamin; Chi D Hornik; Rachel G Greenberg Journal: J Perinatol Date: 2020-10-08 Impact factor: 2.521
Authors: Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin Journal: Curr Drug Metab Date: 2013-02 Impact factor: 3.731
Authors: Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin Journal: Paediatr Drugs Date: 2014-02 Impact factor: 3.022